RCKT Relative Valuation
RCKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCKT is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for RCKT's competitors is 117.99, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT) exhibits a P/S ratio of 115.67, which is -1.96% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
FSUN
Firstsun Capital Bancorp
37.020
USD
+0.05%
IRS
IRSA Inversiones y Representaciones SA
15.770
USD
+0.57%
ARRY
Array Technologies Inc
7.670
USD
+5.57%
PENG
Penguin Solutions Inc
18.850
USD
+0.59%
EMBC
Embecta Corp
12.290
USD
+5.77%
LQDA
Liquidia Corp
17.020
USD
-0.06%
IGIC
International General Insurance Holdings Ltd
23.820
USD
+0.51%
PSFE
Paysafe Ltd
12.440
USD
-2.05%
OBK
Origin Bancorp Inc
33.890
USD
-0.76%
PDM
Piedmont Office Realty Trust Inc
6.790
USD
-1.31%
FAQ
Is Rocket Pharmaceuticals Inc (RCKT) currently overvalued or undervalued?
Rocket Pharmaceuticals Inc (RCKT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 115.67 is considered Overvalued compared with the five-year average of 713.16. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 2.91 to 5.80 according to relative valuation methord. Compared to the current price of 6.85 USD , Rocket Pharmaceuticals Inc is Overvalued By 18.02% .
What is Rocket Pharmaceuticals Inc (RCKT) fair value?
How does RCKT's valuation metrics compare to the industry average?
What is the current P/B ratio for Rocket Pharmaceuticals Inc (RCKT) as of May 21 2025?
What is the current FCF Yield for Rocket Pharmaceuticals Inc (RCKT) as of May 21 2025?
What is the current Forward P/E ratio for Rocket Pharmaceuticals Inc (RCKT) as of May 21 2025?